Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2008-05-13
2008-05-13
Marschel, Ardin H. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
Reexamination Certificate
active
07371780
ABSTRACT:
Calphostin C is used to treat subjects for cancer which is resistant to treatment by other forms of chemotherapeutic drugs, for example breast or uterine cancer, or other cancers characterized by tumor cells that have a defect in an apoptotic regulatory pathway which renders said cells resistant to at least some other forms of chemotherapeutic treatment. The other chemotherapeutic drug used with calphostin C is selected from the group comprising taxanes and anthracyclines, such as paclitaxel or doxorubicin. The use may take the form of administering calphostin C and then subjecting the patient to photodynamic therapy (PDT).
REFERENCES:
patent: 5972598 (1999-10-01), Chaudhary et al.
patent: WO 94/04541 (1994-03-01), None
Sausville et al. Contributions of human tumor xenografts to anticancer drug development. Cancer Research, 2006, vol. 66, pp. 3351-3354.
Johnson et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. British J. of Cancer, 2001, 84(10):1424-1431.
Avendano C, Menendez JC: Inhibitors of Multidrug Resistance to Antitumor Agents (MDR). Curr. Med. Chem. 9, 159-193, 2002.
Fukuda T, Kamishima T, Kakihara T, Ohnishi Y, Suzuki T: Characterization of Newly Established Human Myeloid Leukemia Cell Line (KF-19) and its Drug Resistant Sublines. Leuk. Res. Vol. 20, No. 11/12, 931-939, 1996.
Boesch D, Muller K, Pourtier-Manzanedo A, Loor F: Restoration of Daunomycin Retention in Multidrug-Resistant P388 Cells by Submicromolar Concentrations of SDZ PSC 833, a Nonimmunosuppressive Cyclosporin Derivative. Exp. Cell Res. 196, 26-32, 1991.
Boesch D, Gaveriaux C, Jachez B, Pourtier Manzanedo A, Bollinger P, Loor F: In Vivo Circumvention of P-Glycoprotein-mediated Multidrug Resistance of Tumor Cells with SDZ PSC 833. Cancer Res. 51, 4226-4233, 1991.
Efferth T, Fabry U, Osieka R: Apoptosis and resistance to daunorubicin in human leukemic cells. Leukemia 11, 1180-1186, 1997.
Sikic BI.: Modulation of Multidrug Resistance: A Paradigm for Translational Clinical Research. Oncology vol. 13, 183-187, 1999.
Ogretmen B, Safa AR: Down-regulation of apoptosis-related bcl-2 but not bcl-xL or bax proteins in multidrug resistant MCF-7/Adr human breast cancer cells. Int. J. Cancer 67, 608-614, 1996.
Ikemoto H, Tani E, Matsumoto T, Nakano A, Furuyama J: Apoptosis of human glioma cells in response to calphostin C, a specific protein kinase C inhibitor. J. Neurosurg vol. 83, 1008-1016, 1995.
Zhu DM, Narla RK, Fang WH, Chia NC, Uckun FM: Calphostin C Triggers Calcium-Dependent Apoptosis in Human Acute Lymphoblastic Leukemia Cells. Clin. Cancer Res. Vol. 4, 2967-2976, 1998.
Jarvis WD, Turner AJ, Povirk LF, Traylor RS, Grant S: Induction of Apoptotic DNA Fragmentation and Cell Death in HL-60 Human Promyelocytic Leukemia Cells Pharmacological Inhibitors of Protein Kinase C. Cancer Res. 54, 1707-1714, 1994.
Ikemoto H, Tani E, Ozaki I, Kitagawa H, Arita N: Calphostin C-mediated translocation and Integration of Bax into mitochondria induces cytochromecrelease before mitochondrial dysfunction. Cell Death Differ. 7, 511-520, 2000.
LaRue JM, Stratagoules ED, Martinez JD: Deoxycholic acid-induced apoptosis is switched to necrosis by bcl-2 and calphostin C. Cancer Lett. 152, 107-113, 2000.
Pollack IF, Kawecki S: The effect of calphostin C, a potent photodependent protein kinase C inhibitor, on the proliferation of glioma cells in vitro. J. of Neuro-Oncology 31, 255-266, 1997.
Hu DE, Fan TP: Protein kinase C Inhibitor calphostin C prevents cytokine-induced angiogenesis in the rat. Inflammation vol. 19, No. 1, 39-54, 1995.
Chen CL, Tai HL, Zhu DM, Uckun FM: Pharmacokinetic Features and Metabolism of Calphostin C, A Naturally Occurring Perylenequinone with Antileukemic Activity. Pharm. Res. vol. 16, No. 7 1003-1009, 1999.
da Rocha AB, Mans DR, Regner A, Schwartsmann G: Targeting Protein Kinase C: New Therapeutic Opportunities Against High-Grade Malignant Gliomas? The Oncologist 7, 17-33, 2002.
Traci P. Beck, Edward J. Kirsh, Steven J. Chmura, David A. Kovar, Theodore Chung, Carrie W. Rinker-Schaeffer, Walter M. Stadler; In Vitro Evaluation of Calphostin C as a Novel Agent for Photodynamic Therapy of Bladder Cancer; Basic Science Elsevier Science Inc.; Apr. 16, 1999; 573-577.
Zita Dubauskas, Traci P. Beck, Steven J. Chmura, David A. Kovar, Mithra M. Kadkhodaian, Maneesh Shrivastav, Theodore Chung, Walter M. Stadler, Carrie W. Rinker-Schaeffer; Activated Calphostin C Cytotoxicity is Independent of p53 Status and in Vivo Metastatic Potential; Clinicai Cancer Research; Oct. 1998; vol. 4, 2391-2398.
Sudhir Gupta, Keyur Patel, Harpreet Singh, Sastry Gollapudi; Effect of Calphostin C (PKC inhibitor) on Daunorubicin Resistance in P388/ADR and HL60/AR Cells: Reversal of Drug Resistance Possibly Via P-glycoprotein; Cancer Letters 76 Elsevier Scientific Publishers Ireland; 1994; 139-145.
Eiji Kobayashi, Katsuhiko Ando, Hirofumi Nakano, Takao Iida, Hiroe Ohno, Makoto Morimoto, Tatsuya Tamaoki; Calphostins (UCN-1028), Novel and Specific Inhibitors of Protein Kinase C I. Fermentation, Isolation, Physico-Chemical Properties and Biological Activities; The Journal of Antibiotics; Oct. 1989; 1470-1474.
Sabina Sperandio, Ian de Belle, Dale E. Bredesen; An Alternative, Nonapoptotic Form of Programmed Cell Death; PNAS Dec. 19, 2000; vol. 97, No. 26; 14376-14381.
Suresh V. Ambudkar, Saibal Dey, Christine A. Hrycyna, Muralidhara Ramachandra, Ira Pastan, Michael M. Gottesman; Biochemical, Cellular, and Pharmacological Aspects of the Multidrug Transporter; 1999; 39:361-98; Annu. Rev Pharmacol. Toxicol.
Susan E. Bates, Jong Seok Lee, Bruce Dickstein, Mary Spolyar, Antonio T. Fojo; Differential Modulation of P-Glycoprotein Transport by Protein Kinase Inhibition; May 21, 1993; 32, 9156-9164; Biochemistry 1993 American Chemical Society.
April L. Blajeski, Timothy J. Kottke, Scott H. Kaufmann; A Multistep Model for Paclitaxel-Induced Apoptosis in Human Breast Cancer Cell Lines; 2001; 277-288; Experimental Cell Research Academic Press.
Antony Chadderton, David J. Villeneuve, Stefan Gluck, Angie F. Kirwan-Rhude, Brian R. Gannon, David E. Blais, Amadeo M. Parissenti; Role of Specific Apoptotic Pathways in the Restoration of Paclitaxel-Induced Apoptosis by Valspodar in Doxorubicin-Resistant MCF-7 Breast Cancer Cells; 2000; 59:231-244; Breast Caner Research and Treatment Kluwer Academic Publishers.
Ann-Lii Cheng, Shuang-En Chuang, Robert L. Fine, Kun-Huei Yeh, Chao-Ming Liao, Jong-Ding Lay, Ding-Shinn Chen; Inhibition of the Membrane Translocation and Activation of Protein Kinase C, and Potentiation of Doxorubicin-Induced Apoptosis of Hepatocellular Carcinoma Cells by Tamoxifen; 1998; vol. 55 pp. 523-531; Biochemical Pharmacology Elsevier Science.
Sarah Childs, Victor Ling; the MDR Superfamily of Genes and Its Biological Implications; 1994; 21-36; Important Advances in Oncology Lippincott Company, Philadelphia.
Amy S. Clark, Kip A. West, Peter M. Blumberg, Phillip A. Dennis; Altered Protein Kinase C (PKC) Isoforms in Non-Small Cell Lung Cancer Cells: PKCδ Promotes Cellular Survival and Chemotherapeutic Resistance; Feb. 15, 2003; 63, 780-786; Cancer Research Advances in Brief.
S. P. C. Cole, G. Bhardwaj, J. H. Gerlach, J. E. Mackie, C. E. Grant, K. C. Almquist, A. J. Stewart, E. U. Kurz, A. M. V. Duncan, R. G. Deeley; Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line; Dec. 4, 1992; vol. 258, 1650-1654; Science.
Gwenaëlle Conseil, Joseé Maria Perez-Victoria, Jean-Michel, Francisco Gamarro, André Goffeau, Johann Hofmann, Attilio Di Pietro; Protein Kinase C Effectors Bind to Multidrug ABC Transporters and Inhibit Their Activity; Dec. 13, 2000, 2001; 40, 2564-2571; American Chemical Society.
John Crown; Nonanthracycline Containing Docetaxel-Based Combinations in Metastatic Breast Cancer; Mar. 5, 2001; 2001, 6(suppl 3) 17-21; The Oncologist.
Christina P. da Silva, Catarina R. de Oliveira, Maria da Conceição P. de Lima; Apoptosis as a Mechanism of Cell Death Induced by Different Chemotherapeutic Drugs in Human Leukemic T-Lymphoc
Anderson James D.
Brinks Hofer Gilson & Lione
Marschel Ardin H.
LandOfFree
Use of calphostin C to treat drug-resistant tumor cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of calphostin C to treat drug-resistant tumor cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of calphostin C to treat drug-resistant tumor cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2775439